2.61
-0.01
(-0.57%)
Real-time:
10:21AM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 2.58 - 2.66 |
| 52 week | 2.25 - 14.08 |
| Open | 2.61 |
| Vol / Avg. | 17,828.00/2.00M |
| Mkt cap | 135.04M |
| P/E | - |
| Div/yield | - |
| EPS | -2.56 |
| Shares | 51.84M |
| Beta | 0.77 |
| Inst. own | 89% |
Events
Jun 11, 2013
AVEO Oncology Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma -
Jun 5, 2013
AVEO Oncology Conference Call to Discuss Strategic Restructuring -
May 2, 2013
AVEO Oncology Conference Call -
Apr 29, 2013
Q1 2013 AVEO Oncology Earnings Release
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -10552.63% | -593.15% |
| Operating margin | -10264.71% | -578.85% |
| EBITD margin | - | -552.18% |
| Return on average assets | -62.82% | -45.53% |
| Return on average equity | -105.12% | -66.80% |
| Employees | 219 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
AVEO Pharmaceuticals, Inc. is a cancer therapeutics company discovering, developing and commercializing targeted cancer therapies. The Company�s Human Response Platform, a method of building preclinical models of human cancer, provides the Company with insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. Tivozanib is the Company�s lead product candidate, which the Company partnered with Astellas Pharma Inc. (Astellas) during the year ended December 31, 2011. Tivozanib is an inhibitor of all three vascular endothelial growth factor (VEGF) receptors that is designed to optimize VEGF blockade while minimizing off-target toxicities. In January 2012, the Company announced data from its global, phase III clinical trial of tivozanib, a therapy for first-line treatment in renal cell carcinoma (RCC), which the Company refers to as the TIVO-1 study.
Officers and directors
| Anthony B. Evnin Ph.D. | Independent Chairman of the Board | |
| Tuan Ha-Ngoc | President, Chief Executive Officer, Director | |
| David Johnston MBA | Chief Financial Officer | |
| Elan Ezickson | Chief Operating Officer, Executive Vice President | |
| Joseph Vittiglio | Senior Vice President, General Counsel | |
| Mary Ellen Jones | Senior Vice President - Human Resources | |
| Jeno Gyuris Ph.D. | Chief Scientific Officer | |
| Michael P. Bailey M.B.A. | Chief Commercial Officer | |
| William J Slichenmyer M.D | Chief Medical Officer | |
| Robert S. Epstein M.D. | Director |